Molly Robb

Home / Meet the team / Molly Robb

Molly A. Robb is a Partner at Calibre One specializing in the Healthcare and Life Sciences practice based out of the Boston office.  For the past 20 years, Molly has worked with Venture Capital and Private Equity firms in helping place Board, CEO and C-suite positions into life sciences organizations that compete in biotechnology, pharmaceutical, medical devices, diagnostics/tools and digital health/healthtech.  She serves clients ranging from early-stage, emerging growth and public companies as well as private equity and venture capital funds that specialize in making investments into companies that focus on innovation in Oncology, Alzheimer’s Disease, Neurodegenerative Diseases, Rare Diseases and Cell and Gene Therapy.

Prior to joining Calibre One, Molly was a Managing Director with BioQuest, part of The Diversified Search Group, working both the life sciences sector recruiting senior-level operating leaders and as a member of the Financial Services practice, where she recruited healthcare investors into public and private capital investment funds.  Earlier in her career, Molly worked at Heidrick and Struggles in the Healthcare Private Equity and Venture Capital practice and with Korn Ferry International in their Life Sciences practice working out of the San Francisco and Los Angeles offices. 

Molly obtained her bachelor’s degree in Journalism from the University of Wisconsin-Madison with a double emphasis on Advertising and Mass Communications. 

Active in the healthcare ecosystem, Molly is an avid supporter for the Alzheimer’s Drug Discovery Foundation (ADDF), a regular speaker and frequent webinar presenter on career management for the Wharton Healthcare Management Alumni Association and has volunteered as a Business Mentor for C-Sweetener (part of HLTH Foundation), a mentoring organization with a charter to prepare women leaders for the healthcare C-suite.   More recently, due to the diagnosis of a close family member, Molly has volunteered her time to serve as a Strategic Advisor to Invincible Vision, a patient-led, nonprofit organization focused on serving the global Bietti’s Crystalline Dystrophy (BCD) community.  Invincible Vision is dedicated to raising awareness of this rare, often misdiagnosed, genetic eye disease that causes blindness for 100,000 people globally and is hoping to advance BCD gene therapy research from pre-clinical study into human clinical trials.